UNSPSC 51314377: Phenylephrine/potassium guaiacolsulfonate/promethazine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.

UNSPSC 51314377 Phenylephrine/potassium guaiacolsulfonate/promethazine is a Commodity code that in recent state and local activity covers acquisition of pharmaceuticals and related health-supply products for public health initiatives, emergency response, and community health programs. State and local governments procuring under this code include county health departments, state health agencies, and cooperative purchasing alliances serving multiple jurisdictions. The solicitations show a mix of direct pharmaceutical procurement, drug deactivation systems, and participation in multi-state generic pharmaceutical contracts where manufacturers supply products through authorized wholesalers to government facilities.

Recent activity spans Florida, Texas, and Minnesota-based cooperative arrangements. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, with a July 26, 2023 response deadline (note: the posted and due dates in the source appear inconsistent), seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; vendors must include all shipping and delivery costs and comply with E-Verify and drug-free workplace certifications. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor information on direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager and wholesaler arrangements, as a preliminary step before formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson; vendors must certify cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two authorized wholesalers, and accept a 3 percent administrative fee, with pricing weighted at 75 percent of the evaluation.